MCRIi035-B-2

MCRIi-TC160154-GC-cl5.30.4

The cell line is not validated yet.

General

Cell Line

hPSCreg name MCRIi035-B-2
Cite as:
MCRIi035-B-2
Alternative name(s)
MCRIi-TC160154-GC-cl5.30.4
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 20th January 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Murdoch Children's Research Institute (MCRI)
Owner Murdoch Children's Research Institute (MCRI)
Distributors
Derivation country Australia

General Information

Projects
* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity European

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Genetic variants
TRAPPC4 (target)
hg19:chr11:g.118890966A>G
NM_016146.5; c.454+3A>G
Homozygous
https://www.ncbi.nlm.nih.gov/clinvar/variation/812649/
31794024, 32901138

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

Donor Relations

Other cell lines of this donor

Ethics

Also have a look at the ethics information for the parental line MCRIi035-B .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Thermo Fisher Scientific
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line MCRIi035-B.

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
Unknown

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA

Other

Selection criteria for clones Manually. Morphology and growth then sequencing and characterisation
Derived under xeno-free conditions
Yes
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
CO2 Concentration 5 %
Medium TeSR™ E8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
SOX17
Yes
CXCR4
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
CXCR4
Yes
Brachyury (T)
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
PAX6
Yes
nestin
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
Arr(X,1-22)x2
Passage number: <25
Karyotyping method: Array CGH

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • NEDESBA
  • NEURODEVELOPMENTAL DISORDER WITH EPILEPSY, SPASTICITY, AND BRAIN ATROPHY
Genetic modifications
Isogenic modification
hg19:chr11:g.118890966A>G
NM_016146.5; c.454+3A>G
Heterozygous
Heterozygous gene correction of the TRAPPC4 NM_016146.5; c.454+3A>G variant. Heterozygous carriers are clinically unaffected.
Repaired